Alginate Microcapsules for Sustained Alpha-CGRP Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The short half-life of α-CGRP in human plasma and the non-applicability of osmotic pumps in humans limit the use of α-CGRP as a therapeutic agent for long-term treatment of cardiovascular diseases, necessitating a novel drug delivery system to maintain constant peptide levels and extend therapeutic effects.
Innovation Solution
Development of alginate-based microcapsules using the electrospray method to encapsulate α-CGRP, which are stable for extended periods, biologically active, and tunable for controlled release, allowing subcutaneous administration and potential use in cardiovascular disease treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If α-CGRP is administered systemically, then blood pressure is lowered and cardiovascular function is improved, but the half-life is very short due to rapid degradation by endopeptidases
Solution Approach 1:
The patent uses alginate polymer as an intermediary carrier to protect α-CGRP from degradation. The microcapsules serve as a mediator that shields the peptide from endopeptidases while allowing controlled release, thereby extending its half-life and maintaining therapeutic effects.
Solution Approach 2:
The patent changes the physical state and delivery parameters of α-CGRP by encapsulating it in alginate microcapsules. This transformation from direct peptide administration to encapsulated controlled-release formulation fundamentally alters the pharmacokinetic parameters, extending half-life from minutes to sustained release over time.
2Duration of action of moving object
If osmotic pumps are used for long-term α-CGRP delivery, then constant peptide levels can be maintained, but the system is not applicable in humans
Solution Approach 1:
The patent replaces the complex, non-applicable osmotic pump system with simple, biodegradable alginate microcapsules that can be administered via injection. These microcapsules provide sustained release without requiring complex mechanical systems, making them suitable for human clinical use.
3Stability of the object's composition
If α-CGRP is encapsulated in alginate polymer, then stability and controlled release are achieved, but the complexity of the delivery system increases
Solution Approach 1:
The patent uses alginate polymer to form flexible microcapsule shells that encapsulate α-CGRP. These thin-film microcapsules provide protection and controlled release functionality while maintaining simplicity in structure and administration, avoiding the need for complex mechanical delivery systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The alginate-α-CGRP microcapsules provide sustained release of α-CGRP, maintaining therapeutic levels and reducing blood pressure, while being non-toxic and effective in improving cardiac functions and reducing apoptosis and oxidative stress in heart failure models, thus offering a promising treatment for cardiovascular diseases.
Implementation Method 1
encapsulated using an electrospray method
Implementation Method 2
alginate-based microcapsulation
Data Source
AI summary
Methods and systems for delivering a very potent vasodilator that has the ability to treat and prevent heart failure including delivering microcapsules containing α-CGRP, which show no toxicity and lowers blood pressure similar to the native peptide, where this new compound could greatly enhance the lifespan of patients suffering from heart failure.